Abstract

Background Taiwan has the highest renal disease incidence and prevalence in the world.We evaluated the association of statin and renin-Angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001-2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins.We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): Age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose-response relationship, we categorized only statin or RASI use into four groups in each cohort: <28 (nonusers), 28-90, 91-365, and >365 cumulative defined daily doses (cDDDs). Results In the main model, PS-Adjusted hazard ratios (aHRs; 95% confidence intervals [CIs]) for dialysis risk were 0.57 (0.50-0.65), 0.72 (0.53-0.98), and 0.47 (0.41-0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at >365cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95% CI: 0.54-0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirinwas used. Conclusion Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk.

Original languageEnglish
Article numbere0162588
JournalPLoS One
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

renin-angiotensin system
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dialysis
Angiotensins
Renin-Angiotensin System
dialysis
Renin
dosage
metformin
hypertension
Propensity Score
Taiwan
confidence interval
Metformin
calcium channel blockers
drugs
antihypertensive agents
Comorbidity
diuretics
aspirin

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Statins and renin angiotensin system inhibitors dose-dependentlyprotect hypertensive patients against dialysis risk. / Liu, Ju Chi; Hsu, Yi Ping; Wu, Szu Yuan.

In: PLoS One, Vol. 11, No. 9, e0162588, 01.09.2016.

Research output: Contribution to journalArticle

@article{b5549d224b064b13b16cd6d732999ea4,
title = "Statins and renin angiotensin system inhibitors dose-dependentlyprotect hypertensive patients against dialysis risk",
abstract = "Background Taiwan has the highest renal disease incidence and prevalence in the world.We evaluated the association of statin and renin-Angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001-2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins.We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): Age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose-response relationship, we categorized only statin or RASI use into four groups in each cohort: <28 (nonusers), 28-90, 91-365, and >365 cumulative defined daily doses (cDDDs). Results In the main model, PS-Adjusted hazard ratios (aHRs; 95{\%} confidence intervals [CIs]) for dialysis risk were 0.57 (0.50-0.65), 0.72 (0.53-0.98), and 0.47 (0.41-0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at >365cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95{\%} CI: 0.54-0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirinwas used. Conclusion Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk.",
author = "Liu, {Ju Chi} and Hsu, {Yi Ping} and Wu, {Szu Yuan}",
year = "2016",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0162588",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Statins and renin angiotensin system inhibitors dose-dependentlyprotect hypertensive patients against dialysis risk

AU - Liu, Ju Chi

AU - Hsu, Yi Ping

AU - Wu, Szu Yuan

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background Taiwan has the highest renal disease incidence and prevalence in the world.We evaluated the association of statin and renin-Angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001-2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins.We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): Age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose-response relationship, we categorized only statin or RASI use into four groups in each cohort: <28 (nonusers), 28-90, 91-365, and >365 cumulative defined daily doses (cDDDs). Results In the main model, PS-Adjusted hazard ratios (aHRs; 95% confidence intervals [CIs]) for dialysis risk were 0.57 (0.50-0.65), 0.72 (0.53-0.98), and 0.47 (0.41-0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at >365cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95% CI: 0.54-0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirinwas used. Conclusion Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk.

AB - Background Taiwan has the highest renal disease incidence and prevalence in the world.We evaluated the association of statin and renin-Angiotensin system inhibitor (RASI) use with dialysis risk in hypertensive patients. Methods Of 248,797 patients who received a hypertension diagnosis in Taiwan during 2001-2012, our cohort contained 110,829 hypertensive patients: 44,764 who used RASIs alone; 7,606 who used statins alone; 27,836 who used both RASIs and statins; and 33,716 who used neither RASIs or statins.We adjusted for the following factors to reduce selection bias by using propensity scores (PSs): Age; sex; comorbidities; urbanization level; monthly income; and use of nonstatin lipid-lowering drugs, metformin, aspirin, antihypertensives, diuretics, and beta and calcium channel blockers. The statin and RASI use index dates were considered the hypertension confirmation dates. To examine the dose-response relationship, we categorized only statin or RASI use into four groups in each cohort: <28 (nonusers), 28-90, 91-365, and >365 cumulative defined daily doses (cDDDs). Results In the main model, PS-Adjusted hazard ratios (aHRs; 95% confidence intervals [CIs]) for dialysis risk were 0.57 (0.50-0.65), 0.72 (0.53-0.98), and 0.47 (0.41-0.54) in the only RASI, only statin, and RASI + statin users, respectively. RASIs dose-dependently reduced dialysis risk in most subgroups and in the main model. RASI use significantly reduced dialysis risk in most subgroups, regardless of comorbidities or other drug use (P < 0.001). Statins at >365cDDDs protected hypertensive patients against dialysis risk in the main model (aHR = 0.62, 95% CI: 0.54-0.71), regardless of whether a high cDDD of RASIs, metformin, or aspirinwas used. Conclusion Statins and RASIs independently have a significant dose-dependent protective effect against dialysis risk in hypertensive patients. The combination of statins and RASIs can additively protect hypertensive patients against dialysis risk.

UR - http://www.scopus.com/inward/record.url?scp=84992378376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992378376&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0162588

DO - 10.1371/journal.pone.0162588

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0162588

ER -